abs281.txt	there	is	a	rising	evidence	that	the	proverbial	statement		no	pain		no	gain		firstcoined	at	the	light	of	pioneering	clinical	experiences	with	canonicalchemotherapy	still	holds	true	in	the	era	of	modern	treatments	of	cancer		thisclose	relationship	between	the	occurrence	of	specific	drug-related	toxicity	andtreatment	outcome	has	been	confirmed	since	then	with	a	large	variety	oftreatments		ranging	from	cytotoxics		hormonotherapy		targeted	therapy	and	muchinterestingly	even	with	the	latest	immune	checkpoint	inhibitors		in	the	currentcontext	of	precision	medicine		and	along	with	the	constant	quest	for	identifyingpredictive	biomarkers		close	monitoring	of	treatment-related	toxicities	couldtherefore	be	convenient	to	help	predicting	therapeutic	response		but	presentsseveral	caveats		the	purpose	of	this	review	is	to	briefly	describe	theserelationships	across	the	different	treatments		to	comment	on	possible	underlyingmechanisms	and	to	comment	on	possible	strategies	aiming	at	exploiting	thisrelationship	while	keeping	the	maximal	safety	ensured	in	patients	with	cancer		inparticular		this	review	will	investigate	on	how	drug	exposure	along	with	germinaland	somatic	genetic	issues	does	impact	on	the		no	pain		no	gain		aphorism		andwhy	the	temptation	to	use	treatment-related	toxicities	as	a	cheap	and	convenientway	to	predict	clinical	outcome	or	to	adapt	dosing	should	be	resisted		we	doadvocate	instead	for	developing	comprehensive	genomic	support	along	withextensive	biomathematical	modeling	to	better	customize	dosing	and	shift	towards	anew		no	pain		maximal	gain		paradigm	
